| Literature DB >> 35559129 |
Kathleen R Sheridan1, Michael A Lane2,3, Thomas J Kim4, Joshua C Eby5.
Abstract
Background: Although engagement of infectious disease physicians has been demonstrated to improve clinical outcomes in a variety of disease states, the extent of infectious disease (ID) physician engagement in quality improvement (QI) or their knowledge of QI has not been assessed.Entities:
Keywords: clinical practice; measurement; quality; value
Year: 2021 PMID: 35559129 PMCID: PMC9088501 DOI: 10.1093/ofid/ofab515
Source DB: PubMed Journal: Open Forum Infect Dis ISSN: 2328-8957 Impact factor: 4.423
Survey Questions and Answers
| Question | Answer Options |
|---|---|
| 1. How are you currently involved in quality measurement or improvement work at your hospital/practice? (select all that apply) | A.\tNot actively involved; I am not sure if my practice/facility collects quality data on my care |
| B.\tNot actively involved, but I know that my practice/facility collects data on my care | |
| C.\tMy practice/hospital uses an outside vendor to collect data | |
| D.\tI receive reports about the quality of care that I deliver | |
| E.\tI participate in quality improvement projects | |
| F.\tI serve on a quality improvement oversight or review committee | |
| 2. Select all the barriers to your participation in quality improvement. If you participate in quality improvement, select the barriers that prevent you from greater or more successful participation. | A.\tMortality for all patients you provide care to |
| B.\tMortality for patients with specific infectious disease conditions (eg, | |
| C.\tReadmission rates for all patients you provide care to | |
| D.\tReadmission rates for patients with specific infectious disease conditions
| |
| F.\tUtilization of hospital-specific treatment pathways/order sets | |
| G.\tAntimicrobial utilization | |
| H.\tHealth maintenance (eg, smoking cessation counseling) | |
| I.\tAdherence to treatment standards for non-ID-related conditions (eg, beta-blocker use after MI, smoking cessation) | |
| J.\tOther | |
| 3. Select all quality data that you or your primary practice/hospital collect to measure the safety or quality of care that you deliver. | A.\tOngoing professional practice evaluation |
| B.\tCMS, HRSA, or private payer quality programs | |
| C.\tHospital-based incentive programs | |
| D.\tHospital-based quality improvement effort | |
| E.\tSelf-directed care improvement | |
| F.\tI don’t know | |
| G.\tOther | |
| 4. If you or your hospital/practice collects quality data, what are the data used for? (Select all that apply.) | A.\tLack of validated metrics that reflect ID care |
| B.\tLack of access to data | |
| C.\tLack of support for data collection and/or reporting | |
| D.\tUnclear benefit to participating in QI | |
| E.\tLack of time to complete QI work | |
| F.\tLack of knowledge on how to improve quality | |
| G.\tCost of resources for reporting | |
| H.\tLack of ID-specific data registry | |
| I.\tInfectious disease quality measurement is not an institutional priority | |
| 5. How likely are you to use the following safety and quality metrics if they existed? (1—very unlikely, 5—very likely) | A.\tAntimicrobial use/stewardship |
| B.\tOPAT use and safety | |
| C. | |
| D. | |
| E.\tAdherence to other IDSA-endorsed guideline | |
| F.\tAdherence to HIV care standards (eg, antiretroviral use, OI prophylaxis) | |
| G.\tDevelopment of antimicrobial resistance | |
| H.\tOther (specify) | |
| 6. Would you utilize any of the following resources to improve your knowledge of quality improvement if provided by IDSA? (Select all that apply.) | A.\tWebinars/trainings |
| B.\tFellowship educational tools | |
| C.\tData registry | |
| D.\tIDWeek lectures/workshop | |
| 7. Select all measures that you/your practice reports on either externally or internally. | A.\tStewardship |
| B.\tOPAT | |
| C.\tHIV | |
| D.\tInfection prevention/hospital epidemiology | |
| E.\tAntimicrobial resistance | |
| F. | |
| 8. Rate your familiarity with these quality programs or methods. (1—not at all familiar, 5—extremely familiar) | A.\tMerit-based Incentive Payment Program (MIPS) |
| B.\tAlternative Payment Models (APMs) | |
| C.\tModel for Improvement | |
| D.\tLean Methodology | |
| E.\tSix Sigma | |
| 9. Please describe the location where you deliver the majority of your ID care. | A.\tInpatient |
| B.\tOutpatient | |
| C.\tOther (specify) | |
| 10. How many years have you been in practice? | A.\tMedical student |
| B.\tResident/Fellow | |
| C.\t<5 years out of fellowship | |
| D.\t5–10 years out of fellowship | |
| E.\t10–15 years out of fellowship | |
| F.\t15–20 years out of fellowship | |
| G.\t20–25 years out of fellowship | |
| H.\t≥25 years out of fellowship | |
| 11. What is the size of the facility where you spend the majority of your time? | A.\t<50 beds |
| B.\t50–100 beds | |
| C.\t100–200 beds | |
| D.\t200–400 beds | |
| E.\t400–600 beds | |
| F.\t600–800 beds | |
| G.\t800–1000 beds | |
| H.\t>1000 beds | |
| 12. Would you be willing to participate in a follow-up survey about quality & safety reporting metrics? | A.\tYes |
| B.\tNo |
Abbreviations: CMS, Centers for Medicare and Medicaid Services; HRSA, Heath Resources and Services Administration; ID, infectious disease; IDSA, Infectious Diseases Society of America; MI, myocardial infarction; OI, opportunistic infection; OPAT, outpatient parenteral antibiotic therapy.
Figure 1.Current level of involvement in quality measurement or improvement, by years of practice.
Figure 2.Reported use of quality data, by employment type. Abbreviations: CMS, Centers for Medicare and Medicaid Services; HRSA, Heath Resources and Services Administration.
Figure 3.Barriers to participating in quality improvement. Abbreviations: ID, infectious disease; QI, quality improvement.
Figure 4.Likeliness to use potential ID quality and safety metrics (Likert scale). Abbreviations: ID, infectious disease; IDSA, Infectious Diseases Society of America; OI, opportunistic infection; OPAT, outpatient parenteral antibiotic therapy.